# Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

> **NCT07196579** · PHASE1 · NOT_YET_RECRUITING · sponsor: **TCRx Therapeutics Co.Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Cancer

## Interventions

- **DRUG:** KXV01 TCR Lentinvivo Injection

## Key facts

- **NCT ID:** NCT07196579
- **Lead sponsor:** TCRx Therapeutics Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07196579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07196579, "Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07196579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*